Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...

If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

Mankind Pharma announced a significant 30 percent profit increase for the fourth quarter. This growth was fueled by strong demand for chron...

A rival bidder has publicly questioned the Rajasthan Royals ownership sale process. The US-based entrepreneur Kal Somani and his partners e...

In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...

India's vaccine market is steadily recovering after the impact from Covid-19 and multinationals are back to slowly gaining traction, sugges...

Indian vaccine maker Bharat Biotech said on Friday that the Russia-Ukraine conflict had not impacted the company's supply chains so far.

Under the agreement, Ocugen will have the US rights to the vaccine candidate and will be responsible for clinical development, regulatory a...

Gardasil and Crevarix, both human papilloma virus (HPV) vaccines, are being marketed in India by MSD Pharmaceutical.

India had revenue of $ 665 million in this space which was expected to reach $ 800 million soon, said Steven H Myint.

The deal between Sanofi its French owners Meriuex Alliance values the unlisted Indian company at Rs 3,740 crore, or about eight times its p...

Indian vaccine makers are setting their sights on tapping the growing US market after the Obama administration committed $300 million for i...

Panacea Biotec is learnt to have bagged a $35-million drug supply order from UNICEF to supply pentavalent vaccines, the first Indian compan...